As health system dealmaking stays steady in 2026, Integris Health is joining Risant Health to accelerate value-based care. The partnership represents an integration of Risant Health’s capabilities into Integris’ existing system, rather than a traditional merger. The post Integris Health to Join Risant Health as Health System Dealmaking Stays Active appeared first on MedCity News.

Why should Medicare determine who is qualified to provide remote monitoring by asking who employs the nurse, rather than who is accountable for the patient’s care? The post CMS Is Regulating the Wrong Thing — Here’s How to Fix Remote Patient Monitoring Without Losing the Care appeared first on MedCity News.

[Sponsored] BTK inhibitor has become an important treatment option for certain B-cell malignancies. The post How Innovation in BTK Inhibitor Development Is Improving Treatment Outcomes appeared first on MedCity News.

Companies aren’t slowing down to ask if AI is ready for mental health; they’re racing to build it in. Encoding the same unexamined standards into these tools means repeating the systemic issues marginalized groups have lived with for far too long. The post Mental Health Care Was Never Built for Everyone — AI Won’t Fix That appeared first on MedCity News.

Midstream’s Series A round was led by Valtruis, and included participation from Andreessen Horowitz (a16z), Foundry and CommonSpirit Ventures. The post Midstream Health Snags $20M to Provide Health Systems More Financial Stability appeared first on MedCity News.

Setara Biosciences’ lead program is a potential treatment for the rare neuromuscular disorder Charcot-Marie-Tooth disease type 2C and the prevalent condition overactive bladder. This small molecule came from Actio Biosciences, which was recently acquired by Jazz Pharmaceuticals. The post Rare Disease Biotech Setara Starts Out With $90M and a Lead Drug in the Clinic appeared first on MedCity News.

Medical Microinstruments (MMI) has raised $125 million in Series D financing to expand the reach of its Symani Surgical System and investigate new applications for microsurgery, including an experimental approach to treat Alzheimer’s disease. The post MMI Raises $125M to Expand Robotic Microsurgery and Explore New Treatments appeared first on MedCity News.

One question on everyone’s mind is what the impact of the midterm elections will be on the US healthcare system in the near and long term – here are 3 possible outcomes The post What the Midterms Mean for Healthcare and the Investors Betting on It appeared first on MedCity News.

An employer that treats board disclosure, community benefit reporting, and contracting terms as three separate conversations is missing that they are the same conversation. The post Prestige Is a Business Model appeared first on MedCity News.

The Department of Labor finalized a rule that seeks to bring more transparency into PBM compensation. The post Employer, Pharmacy Advocates Applaud DOL Final Rule on PBMs appeared first on MedCity News.

Bambusa Therapeutics’ IPO cash will support its pipeline of bispecific antibodies designed to offer advantages over currently available monoclonal antibodies. Aspen Neuroscience also debuted on the Nasdaq as it prepares for a pivotal test of its Parkinson’s disease cell therapy. The post Bambusa IPO Brings In $169M to Break Immunology’s ‘Therapeutic Ceiling’ appeared first on MedCity News.

For life science employers who offer these benefits should pay particular attention to new state laws and regulations to ensure continued compliance. The post It’s A TRAP! Employer Concerns for Tuition Reimbursement and Other Employee Repayment Agreements appeared first on MedCity News.

CMS asked the right questions – the ones that will determine whether any future benefit actually reaches these patients. The post A Meaningful Signal on Palliative Care – But Not Yet a Benefit appeared first on MedCity News.

At MedCity INVEST Digital Health, experts from Jona, Labcorp and Evvy discussed the drivers of consumer diagnostics. The post What’s Driving the Rise of Consumer Diagnostics? appeared first on MedCity News.

BioMarin gains rights to a Fabry disease enzyme replacement therapy with potential dosing advantages over products from Sanofi and Chiesi Group. BioMarin’s new clinical-stage asset could reach patients ineligible for the Fabry drug that came with its Amicus Therapeutics acquisition earlier this year. The post BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting Fabry Drug appeared first on MedCity News.